"CASE COMMENTARY ON NOVARTIS AG V. UNION OF INDIA & OTHERS"

This case commentary examines Novartis AG v. Union of India, (2013) 6 SCC 1, a landmark decision on pharmaceutical patentability under Section 3(d) of the Patents Act, 1970. Novartis sought a patent for the beta crystalline form of Imatinib Mesylate, used to treat chronic myeloid leukaemia, claiming enhanced bioavailability. The Supreme Court rejected the claim, holding that "efficacy" for medicines means therapeutic efficacy, not merely improved physical properties or bioavailability. The judgment establishes a strict standard against evergreening, requiring demonstrable enhancement of curative effect for new forms of known substances. It balances intellectual-property protection with public health and access to affordable generic medicines.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-14
DOI
https://doi.org/10.5281/zenodo.24219997
Primary Topic
Intellectual Property Law
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

"CASE COMMENTARY ON NOVARTIS AG V. UNION OF INDIA & OTHERS"

Chandan Sha
Zenodo (CERN European Organization for Nuclear Research)
Intellectual Property Law
article

"CASE COMMENTARY ON NOVARTIS AG V. UNION OF INDIA & OTHERS"

Chandan Sha
article en

Abstract

This case commentary examines Novartis AG v. Union of India, (2013) 6 SCC 1, a landmark decision on pharmaceutical patentability under Section 3(d) of the Patents Act, 1970. Novartis sought a patent for the beta crystalline form of Imatinib Mesylate, used to treat chronic myeloid leukaemia, claiming enhanced bioavailability. The Supreme Court rejected the claim, holding that "efficacy" for medicines means therapeutic efficacy, not merely improved physical properties or bioavailability. The judgment establishes a strict standard against evergreening, requiring demonstrable enhancement of curative effect for new forms of known substances. It balances intellectual-property protection with public health and access to affordable generic medicines.

Zenodo (CERN European Organization for Nuclear Research)
North Bengal University (IN)
Intellectual Property Law
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon